Error message

  • User warning: The following module is missing from the file system: entity. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/
  • User warning: The following module is missing from the file system: entity_token. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/
  • User warning: The following module is missing from the file system: path_breadcrumbs. For information about how to fix this, see the documentation page. in _drupal_trigger_error_with_delayed_logging() (line 1181 of /local/drupal/proteomics/includes/

COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, advance proteome and proteogenome science and technology development through community resources (data and reagent), and accelerate the translation of molecular findings into the clinic. This is achieved through OCCPR-supported programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, and collaborations with international organizations/institutions.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

Revolutionizing Liver Cancer Treatments: The Power of Organoid Models

Proteogenomic characterization of patient tissues has enriched our understanding of liver cancer, uncovering potential therapeutic targets, new subtypes, and offering hope for more effective treatments. However, there remains a gap in translating these findings into clinical practice.

The Cancer Imaging Archive Releases AI-Ready CPTAC Imaging Annotations to Facilitate Imaging-Omics Cancer Research

The Cancer Imaging Archive (TCIA), managed by the National Cancer Institute's Cancer Imaging Program (CIP), collects, curates, and hosts digital histopathology and standard-of-care radiology imaging from CPTAC-enrolled patients to provide data for imaging-omics research.    Algorithmic analysis of...

Illuminating Endometrial Carcinoma through Proteogenomics and Deep Learning

Recent strides in the field of genomics, exemplified by initiatives like The Cancer Genome Atlas (TCGA), have illuminated the genetic landscape of endometrial carcinoma (EC). The identification of four distinct EC...

Introducing a Suite of Pan-Cancer Multi-omic Papers from CPTAC

Researchers from the National Cancer Institute’s (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) have produced a resource of global proteomic and post-translational modifications, whole genome and whole exome sequencing, miRNA and totalRNA sequencing, DNA methylation, imaging, and clinical...

Novel 64-Protein Signature Predicts Treatment Response in High-Grade Serous Ovarian Cancer

In an effort recently published in Cell, CPTAC researchers aimed to identify patients with high-grade serous ovarian cancer (HGSOC) who may not respond to standard therapies. At present, there is no way...

PepQuery2: Empowering Proteomics Researchers with Ultrafast Data Analysis

Recently published in Nature Communications, PepQuery2 is a powerful tool that facilitates fast and targeted identification of both new and existing peptides in proteomics datasets obtained from mass spectrometry experiments. It...

ETH Zürich (Switzerland) and United States National Cancer Institute Sign Extension of MOU for Proteogenomics Cancer Research

The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of an extension to their memorandum of understanding (MOU) for collaborative...

The MONTE Workflow: Enabling Deep Analysis of Sample-Limited Tissues

The limited availability of patient tissue samples poses a constant challenge for omics researchers, particularly in determining which analyses are feasible based on sample input requirements. Existing parallel workflows for multi-omic analyses have yielded valuable insights but are often restricted...

NCI Welcomes Renewed Commitments to the Cancer Moonshot with Taiwan

The United States National Cancer Institute (NCI) and Taiwan are pleased to announce the signing of an extension to their memoranda of understanding (MOUs) for proteogenomics cancer research with Academia Sinica and Chang Gung University. This extension marks a renewed commitment to the collaboration...

Integrated Glycoproteomic Characterization Reveals Molecular Features of ccRCC

Glycosylation is a ubiquitous type of protein modification that is associated with biological functions and diseases, including cancer. Often found on cell surface or secreted into circulation, glycoproteins can be leveraged for diagnosis and treatment.